Page last updated: 2024-12-05

ipriflavone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ipriflavone is a synthetic flavonoid compound with a chemical structure similar to isoflavones found in soy. It is primarily studied for its potential benefits in treating osteoporosis and other bone-related conditions. Research suggests that ipriflavone may promote bone formation and reduce bone resorption by mimicking the effects of estrogen. It is thought to work by inhibiting the breakdown of bone tissue and stimulating the activity of osteoblasts, cells responsible for bone formation. While further research is needed, ipriflavone has shown promising results in clinical trials, particularly in postmenopausal women with osteoporosis. However, it is important to note that ipriflavone is not a substitute for other osteoporosis treatments, such as calcium and vitamin D supplements.'

ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3747
CHEMBL ID165790
CHEBI ID31719
SCHEMBL ID111472
MeSH IDM0071058

Synonyms (116)

Synonym
MLS001146879
HMS3393J15
ipriflavone
MLS000069470 ,
tn-39
osteofix
iprosten
tc-80
osteoquine
osten
fl-113
osteochin
fl 113
7-(1-methylethoxy)-3-phenyl-4h-1-benzopyran-4-one
brn 4754346
ipriflavone [inn:jan]
tc 80
ccris 1920
ipriflavona [inn-spanish]
yambolap
4h-1-benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-
ipriflavonum [inn-latin]
7-isopropoxyisoflavone
quinogin
OPREA1_275552
OPREA1_106310
MLS000759494
NCGC00024094-04
D01338
35212-22-7
ipriflavone (jp17/inn)
osten (tn)
7-isopropoxy-3-phenyl-4h-1-benzopyran-4-one, 97%
smr000059060
NCGC00018139-01
3-phenyl-7-(propan-2-yloxy)-4h-chromen-4-one
HMS2051J15
I0669
chebi:31719 ,
CHEMBL165790
ostivone
nsc-755888
sfbodokjtyaucm-uhfffaoysa-
inchi=1/c18h16o3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12h,1-2h3
3-phenyl-7-propan-2-yloxychromen-4-one
AKOS003627375
NCGC00018139-03
NCGC00018139-04
NCGC00018139-02
tox21_113172
dtxsid5040679 ,
cas-35212-22-7
dtxcid3020679
tox21_111532
7-isopropoxy-3-phenyl-4h-chromen-4-one
A822650
MLS001424060
HMS2234M05
CCG-100963
ipriflavonum
unii-80bj7wn25z
ipriflavona
80bj7wn25z ,
nsc 755888
7-isopropoxy-3-phenyl-4h-1-benzopyran-4-one
F0196-0909
FT-0621442
NCGC00018139-08
ipriflavone [mart.]
ipriflavone [jan]
ipriflavone [who-dd]
ipriflavone [mi]
ipriflavone [inn]
ipriflavone [vandf]
S2422
HMS3371E17
AB00384280-21
MLS006011644
SCHEMBL111472
NC00213
tox21_111532_1
tox21_113172_1
NCGC00018139-07
NCGC00018139-05
7-isopropoxy-isoflavone
7-isopropyloxy-isoflavone
ipriflavon
bdbm43662
cid_3747
3-phenyl-7-propan-2-yloxy-1-benzopyran-4-one
7-isopropoxy-3-phenyl-chromone
3-phenyl-7-propan-2-yloxy-chromen-4-one
ipriflavone (osteofix)
iprivone
cambridge id 6663564
OPERA_ID_1176
mfcd00221719
AC-8130
sr-01000000042
SR-01000000042-2
ipriflavone, analytical standard
HMS3656K19
ipriflavone (jan/inn)
fl113
ipriflavone, inn
(ipriflavone)
HMS3715D04
SW197593-2
CS-6395
HY-N0094
STL512460
DB13618
AS-12306
Q1097778
AMY25650
D70301

Research Excerpts

Overview

Ipriflavone (IPRI) is a non-hormonal, semi-synthetic isoflavone, clinically used in some countries for the treatment and prevention of postmenopausal osteoporosis. Iprflavone is a synthetic flavonoid that has been shown to exert a direct inhibitory effect on osteoclastic activity.

ExcerptReferenceRelevance
"Ipriflavone (IPRI) is a non-hormonal, semi-synthetic isoflavone, clinically used in some countries for the treatment and prevention of postmenopausal osteoporosis."( Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats.
Abady, MM; Abdel-Monem, N; El Demellawy, MA; Ghareeb, DA; Hafez, HS; Hussien, H; Saleh, SR, 2017
)
1.48
"Ipriflavone is a nonhormonal isoflavone derivative currently used as a bone-building agent for prevention and treatment of postmenopausal osteoporosis. "( Determination of the anti-osteoporosis drug ipriflavone in pharmaceutical formulation by stripping voltammetric and chromatographic methods.
Beltagi, AM; El-Desoky, HS; Ghoneim, MM,
)
1.84
"Ipriflavone (IP) is an isoflavone derivative available in several countries for investigational and/or therapeutic use. "( Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
Reginster, JY, 1993
)
3.17
"Ipriflavone is an isoflavone derivative used in the prevention and treatment of postmenopausal and senile osteoporosis in humans. "( Inhibition of parathyroid hormone-stimulated resorption in cultured fetal rat long bones by the main metabolites of ipriflavone.
Bongrani, S; Caruso, P; Civelli, M; Giossi, M, 1996
)
1.95
"Ipriflavone (IP) is an isoflavone derivative that was suggested to have bone-sparing effects in post-menopausal and senile osteoporosis. "( Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters.
Bassleer, CT; Franchimont, NM; Franchimont, PP; Geenen, VG; Henrotin, YE; Reginster, JY, 1996
)
2.13
"Ipriflavone is an original molecule. "( [The ipriflavone story].
György, L; István, H; Marian, EP; Mihály, N, 1995
)
2.25
"Ipriflavone is a synthetic flavonoid that has been shown to exert a direct inhibitory effect on osteoclastic activity and possibly stimulate the osteoblast activity in different experimental models. "( Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
Altieri, P; Bottiglioni, F; Ciaponi, M; de Aloysio, D; Gambacciani, M; Genazzani, AR; Mura, M; Ventura, V, 1997
)
1.97
"Ipriflavone (IP) is an isoflavone derivative with antiosteoporotic activity. "( Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes.
Acerbi, D; Poli, G; Ventura, P,
)
1.82
"Ipriflavone (IP) is a derivative of naturally occurring isoflavones and is marketed as Osteofix for the treatment of osteoporosis in Europe. "( Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet.
Barrett, JS; Morales, RJ; Rohatagi, S; Sawyers, W; Yu, K,
)
1.9
"Ipriflavone is a recently introduced anti-osteoporotic agent extensively metabolized to four major metabolites (M1, M2, M3, M5). "( Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure.
Acerbi, D; Rondelli, I; Ventura, P, 1991
)
2.01

Effects

Ipriflavone (IP) has been widely studied in humans and is effective for inhibiting osteoclastic bone resorption and enhancing osteoblastic bone formation. ipriflavon could have been due to the faster hepatic Cl(int) (because of an increase in the protein expression and/or mRNA level of hepatic CYP1A subfamily)

ExcerptReferenceRelevance
"1. Ipriflavone (IP) has been widely studied in humans and is effective for inhibiting osteoclastic bone resorption and enhancing osteoblastic bone formation. "( Ipriflavone reverses the adverse effects of a low-calcium diet on the histology of the tibia in caged layers.
Li, K; Lv, WT; Ma, LQ; Wang, P; Yang, YH, 2014
)
2.47
"ipriflavone could have been due to the faster hepatic Cl(int) (because of an increase in the protein expression and/or mRNA level of hepatic CYP1A subfamily) and the faster hepatic blood flow rate than controls."( Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin.
Choi, YH; Chung, HJ; Kim, SH; Lee, DY; Lee, I; Lee, MG; Lee, U, 2009
)
1.4
"Ipriflavone has been shown to be effective in reducing bone turnover rate mainly through an inhibition of bone resorption, and has been effect to stimulate of bone formation."( [Ipriflavone].
Kitatani, K; Morii, H, 1998
)
1.93
"Ipriflavone has five major metabolites (M1, M2, M3, M4, and M5)."( Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
Barrett, JS; Rohatagi, S,
)
1.1

Actions

Ipriflavone could inhibit bone resorption and promote bone formation. It increased triglyceride levels and reduced hematocrit at higher doses.

ExcerptReferenceRelevance
"Ipriflavone could inhibit bone resorption and promote bone formation. "( Effects of ipriflavone on postmenopausal syndrome and osteoporosis.
Dong, CL; Du, J; Li, SW; Wu, JF; Zhang, X; Zhang, YP; Zheng, CX, 2010
)
1.8
"Ipriflavone did not cause maternal toxicity, but increased triglyceride levels and reduced hematocrit at higher doses. "( [Effect of ipriflavone on Wistar rats and their litters].
Andrade, AT; Bellei, PM; Guerra, Mde O; Peters, VM; Terra, MM, 2012
)
2.21

Treatment

Ipriflavone treatment remarkably prevented osteoporosis via promoting MSCs osteogenesis in ovariectomized rats. Treatment was not associated with significant changes in serum alkaline phosphatase nor type I collagen telopeptide levels.

ExcerptReferenceRelevance
"Ipriflavone treatment also showed beneficial effects on early osseointegration."( Ipriflavone suppresses NLRP3 inflammasome activation in host response to biomaterials and promotes early bone healing.
Chen, Y; Feng, J; He, F; Li, J; Lin, W; Ning, D; Shi, J; Xie, Z, 2022
)
2.89
"Ipriflavone treatment remarkably prevented osteoporosis via promoting MSCs osteogenesis in ovariectomized rats."( Ipriflavone promotes osteogenesis of MSCs derived from osteoporotic rats.
Gao, AG; Hu, ZJ; Lu, BB; Zhou, YC, 2018
)
2.64
"Ipriflavone treatment was not associated with significant changes in serum alkaline phosphatase nor type I collagen telopeptide levels, two markers of bone turnover."( Ipriflavone improves bone density and biomechanical properties of adult male rat bones.
Abbasi-Jarhomi, SH; Civitelli, R; Dimarogonas, A; Halstead, LR, 1995
)
2.46
"In ipriflavone treated group the patterns of biochemical markers indicated that ipriflavone can restrain the bone remodeling processes and radial bone density showed no significant modification during the 12 month study period."( Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Cappagli, B; Cappelli, N; Felipetto, R; Fioretti, P; Gambacciani, M; Parrini, D; Spinetti, A; Taponeco, F, 1993
)
1.19

Toxicity

Ipriflavone efficaciously alleviated the adverse effects of estrogen deficiency such as bone loss and increase in LDL-C level. The ability of leuprolide therapy to reduce myoma volume was not decreased by ipr iflavone administration.

ExcerptReferenceRelevance
" The incidence of adverse reactions in ipriflavone-treated patients (14."( Efficacy of ipriflavone in established osteoporosis and long-term safety.
Agnusdei, D; Bufalino, L, 1997
)
0.95
" Ipriflavone efficaciously alleviated the adverse effects of estrogen deficiency such as bone loss and increase in LDL-C level, and the ability of leuprolide therapy to reduce myoma volume was not decreased by ipriflavone administration."( Efficacy of ipriflavone in preventing adverse effects of leuprolide.
Aso, T; Chiguchi, M; Ishibashi, T; Somekawa, Y; Wakana, K, 2001
)
1.6
" The safety profiles were associated with adverse events and the number of subject withdrawals due to adverse reactions."( The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
Chen, J; Hu, Q; Huang, S; Long, C; Ning, N; O Klineberg, E; Ran, L; Wu, D; Xu, J; You, X, 2020
)
0.86
" For safety profile, most frequent reactions are gastrointestinal symptoms, but withdrawals due to adverse reactions are similar in both the IP group and placebo control at the same time intervals."( The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
Chen, J; Hu, Q; Huang, S; Long, C; Ning, N; O Klineberg, E; Ran, L; Wu, D; Xu, J; You, X, 2020
)
0.86
" Gastrointestinal symptoms may occur, but adverse drug withdrawal events were not statistically increased when compared with placebo group."( The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
Chen, J; Hu, Q; Huang, S; Long, C; Ning, N; O Klineberg, E; Ran, L; Wu, D; Xu, J; You, X, 2020
)
0.86

Pharmacokinetics

After intravenous and oral administration, the pharmacokinetic parameters of ipriflavone were dose-independent. Protein and mRNA expression of CYP1A2 in the liver, reported to be increased in mutant Nagase analbuminemic rats (NARs), should influence the pharmacodynamic parameters.

ExcerptReferenceRelevance
" Plasma concentration data from a pilot pharmacokinetic study in which 16 healthy male volunteers were administered 200 mg of an ipriflavone corn suspension were used to examine the predictability of this model."( Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
Barrett, JS; Rohatagi, S,
)
0.59
"6 mL/min/kg), and terminal half-life (94."( Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits.
Kim, S; Lee, J; Lee, M, 2000
)
0.57
"To evaluate pharmacokinetic behavior of ipriflavone solid dispersion in rats."( Pharmacokinetics of intragastric ipriflavone solid dispersion in rats.
Li, YP; Pei, YY; Zhang, XY; Zhou, JJ, 1999
)
0.85
" After intravenous and oral administration, the pharmacokinetic parameters of ipriflavone were dose-independent."( Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim, SH; Lee, MG, 2002
)
0.87
" Thus, pharmacokinetic parameters of ipriflavone and its metabolites, M1 and M5, were evaluated in ECLPS rats."( Effects of E. Coli lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites, M1 and M5, after intravenous and oral administration of ipriflavone to rats: decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A
Bae, EJ; Chung, HJ; Kang, HE; Kim, SG; Lee, I; Lee, MG, 2008
)
0.86
" Protein and mRNA expression of CYP1A2 in the liver, reported to be increased in mutant Nagase analbuminemic rats (NARs), should influence the pharmacokinetic parameters of ipriflavone."( Ipriflavone pharmacokinetics in mutant Nagase analbuminemic rats.
Chung, HJ; Kang, HE; Kim, SY; Lee, MG; Yang, KH, 2009
)
1.99
" The method was fully validated and applied to a pharmacokinetic study of ipriflavone."( Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study.
Ding, L; Leng, Y; Wen, A; Yang, L; Yun, C; Zhu, H, 2012
)
0.95

Compound-Compound Interactions

ExcerptReferenceRelevance
" In addition, a low dose of 1 alpha (OH)D3, which did not induce hypercalcemia, in combination with ipriflavone, augmented the stimulatory effect of ipriflavone alone on the bone mass, possibly due to a direct effect of each agent on osteoblastic cells."( Increase in femoral bone mass by ipriflavone alone and in combination with 1 alpha-hydroxyvitamin D3 in growing rats with skeletal unloading.
Notoya, K; Taketomi, S; Tsuda, M; Tsukuda, R; Yoshida, K, 1996
)
0.79

Bioavailability

Ipriflavone is a non-peptidomimetic small molecule AChE inhibitor with an improved bioavailability after systemic administration. It is absorbed from small intestine via the portal route, distributed widely in tissues, metabolized extensively by oxidation, and eliminated from body preferentially in urine.

ExcerptReferenceRelevance
"Ipriflavone administered to rats orally is well absorbed from small intestine via the portal route, distributed widely in tissues, metabolized extensively by oxidation, and eliminated from the body preferentially in urine."( [Pharmacokinetics of ipriflavone].
Ferenc, L; István, S, 1995
)
2.05
" The aim of this study was to compare the bioavailability of IP and its metabolites M1, M2, M3, and M5 at steady-state after administration of 200 mg tablets three times daily and 300 mg Scherer capsules twice daily during meals."( Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes.
Acerbi, D; Poli, G; Ventura, P,
)
0.38
"Model predictions supported the improvement in bioavailability with corn-oil suspension compared to the conventional oral tablet."( Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
Barrett, JS; Rohatagi, S,
)
0.38
"L-1; The relative bioavailability of ipriflavone solid dispersion was 323%."( Pharmacokinetics of intragastric ipriflavone solid dispersion in rats.
Li, YP; Pei, YY; Zhang, XY; Zhou, JJ, 1999
)
0.86
" The extent of absolute oral bioavailability (F) was also independent of oral doses; the mean F value was approximately 24%."( Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim, SH; Lee, MG, 2002
)
0.64
" Moreover, ipriflavone is a non-peptidomimetic small molecule AChE inhibitor with an improved bioavailability after systemic administration, due to its efficient blood-brain barrier permeability in comparison with peptidomimetic inhibitors."( Neuroprotective effect of ipriflavone against scopolamine-induced memory impairment in rats.
Abady, MM; Abdel-Monem, N; El Demellawy, MA; Ghareeb, DA; Hafez, HS; Hussien, H; Saleh, SR, 2017
)
1.15
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Ipriflavone was administered as oral capsules dosed at 200 mg, 3 times a day for 12 months. At lower concentrations metabolites II and III potentiated the cAMP accumulation induced by low doses of parathyroid hormone.

ExcerptRelevanceReference
" Pretreatment of osteoblasts with high concentrations of ipriflavone for 48 h significantly inhibited the cAMP response to parathyroid hormone, producing a shift in the dose-response curve; at lower concentrations metabolites II and III potentiated the cAMP accumulation induced by low doses of parathyroid hormone."( Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line.
Benvenuti, S; Bianchi, S; Brandi, ML; Bufalino, L; Casano, R; Frediani, U; Masi, L; Serio, M; Tanini, A, 1991
)
0.92
" The dosage was 600 mg/day given in three doses and treatment lasted 6 months."( Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Agnusdei, D; Bigazzi, S; Cepollaro, C; Gennari, C; Montagnani, M; Nardi, P; Zacchei, F, 1989
)
0.56
" to 6 rats of each group at a dosage of 25 mg/kg BW."( [Experimental study on the effect of ipriflavone against osteoporosis in ovariectomized rats].
Li, H; Ouyang, Q; Weng, L; Zheng, Z, 1994
)
0.56
" Ipriflavone was administered as oral capsules dosed at 200 mg, 3 times a day for 12 months."( New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
Caserta, D; Moscarini, M; Palermo, P; Patacchiola, F; Spacca, G; Valenti, M, 1994
)
1.44
" The good bioavailability and fluctuation indexes of the Scherer capsules permit a simplification of the dosage scheme, reducing the daily administrations from three times to twice daily, thus improving the patients' compliance."( Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes.
Acerbi, D; Poli, G; Ventura, P,
)
0.38
"The aim of the present work was to design a film dosage form for sustained delivery of ipriflavone into the periodontal pocket."( Periodontal delivery of ipriflavone: new chitosan/PLGA film delivery system for a lipophilic drug.
Conti, B; Genta, I; Modena, T; Pavanetto, F; Perugini, P, 2003
)
0.85
" Dose-response assays determined the three compounds to be 8- to 30-fold less potent than the index Hh pathway inhibitor cyclopamine."( Identification of Hedgehog signaling inhibitors with relevant human exposure by small molecule screening.
Bushman, W; Lipinski, RJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (2 Product(s))

Product Categories

Product CategoryProducts
Vitamins & Supplements2

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
KAL Bone Defense -- 90 Vegetarian CapsulesKALVitamins & SupplementsVitamin C, Biotin, Boron, Ipriflavone, Manganese, Selenium, Vitamin K2024-11-29 10:47:42
Kal Ipriflavone -- 600 mg - 30 TabletsKALVitamins & SupplementsCalcium Citrate, Cellulose, Ipriflavone, stearic acid2024-11-29 10:47:42

Roles (1)

RoleDescription
bone density conservation agentAn agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
isoflavonesAny isoflavonoid with a 3-aryl-1-benzopyran-4-one (3-aryl-4H-chromen-4-one) skeleton and its substituted derivatives.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (59)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency2.34340.007215.758889.3584AID1224835; AID411; AID588342; AID624030
BRCA1Homo sapiens (human)Potency0.63100.89137.722525.1189AID624202
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.87480.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency5.89640.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency18.35640.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency1.56740.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency29.90330.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency2.15100.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743042; AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency8.91250.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency6.30960.00137.762544.6684AID914; AID915
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency0.84130.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency1.45850.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.23870.01237.983543.2770AID1346984
EWS/FLI fusion proteinHomo sapiens (human)Potency33.17340.001310.157742.8575AID1259252; AID1259253
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.28210.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.16210.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency3.01860.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.43390.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID743069; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency17.83950.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency8.70900.00108.379861.1304AID1645840
IDH1Homo sapiens (human)Potency32.64270.005210.865235.4813AID686970
aryl hydrocarbon receptorHomo sapiens (human)Potency4.96610.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.39840.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency0.31620.10009.191631.6228AID1346983
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency1.41250.036619.637650.1187AID2112
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency0.64780.01262.451825.0177AID485313
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.18360.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency5.62343.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency14.12540.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.12360.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency2.86500.037617.082361.1927AID1259364; AID1259388
huntingtin isoform 2Homo sapiens (human)Potency1.58490.000618.41981,122.0200AID2669
DNA polymerase betaHomo sapiens (human)Potency25.11890.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency17.78280.039816.784239.8107AID1454
ras-related protein Rab-9AHomo sapiens (human)Potency0.66900.00022.621531.4954AID485297
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency18.00530.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
survival motor neuron protein isoform dHomo sapiens (human)Potency3.16230.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency794.32800.00419.962528.1838AID2675
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.18830.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency17.83950.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency17.83950.01238.964839.8107AID1645842
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.18830.001551.739315,848.9004AID1259244
TAR DNA-binding protein 43Homo sapiens (human)Potency4.46681.778316.208135.4813AID652104
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency17.83950.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency2.04170.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency1.92430.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency17.83950.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SUMO-1-specific proteaseHomo sapiens (human)IC50 (µMol)57.20000.805019.346187.7000AID488921
SUMO1/sentrin specific peptidase 7Homo sapiens (human)IC50 (µMol)5.35001.64007.264823.9000AID488904
caspase-3 isoform a preproproteinHomo sapiens (human)IC50 (µMol)19.70000.025620.323574.3000AID488901
sentrin-specific protease 8Homo sapiens (human)IC50 (µMol)94.80000.040818.929294.8000AID488903
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)2.51250.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki2.49170.00322.28879.3160AID625207
Macrophage migration inhibitory factorHomo sapiens (human)IC50 (µMol)255.00000.03803.09109.8000AID1877334
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)2.94430.00021.557410.0000AID625243
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)2.51250.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki2.49170.00031.465610.0000AID625207
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
signal transducer and activator of transcription 1-alpha/beta isoform alphaHomo sapiens (human)EC50 (µMol)0.41800.41801.36182.9980AID1397
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (126)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
prostaglandin biosynthetic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cytokine productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of mature B cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
inflammatory responseMacrophage migration inhibitory factorHomo sapiens (human)
cell surface receptor signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of gene expressionMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of protein kinase A signalingMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of macrophage chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
carboxylic acid metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cell migrationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of B cell proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of tumor necrosis factor productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of myeloid cell apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
regulation of macrophage activationMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of apoptotic processMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
innate immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of fibroblast proliferationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationMacrophage migration inhibitory factorHomo sapiens (human)
positive chemotaxisMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of protein metabolic processMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of prostaglandin secretion involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune responseMacrophage migration inhibitory factorHomo sapiens (human)
protein homotrimerizationMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of arachidonic acid secretionMacrophage migration inhibitory factorHomo sapiens (human)
cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorMacrophage migration inhibitory factorHomo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 productionMacrophage migration inhibitory factorHomo sapiens (human)
negative regulation of cellular senescenceMacrophage migration inhibitory factorHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protease bindingMacrophage migration inhibitory factorHomo sapiens (human)
dopachrome isomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine activityMacrophage migration inhibitory factorHomo sapiens (human)
cytokine receptor bindingMacrophage migration inhibitory factorHomo sapiens (human)
protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
chemoattractant activityMacrophage migration inhibitory factorHomo sapiens (human)
identical protein bindingMacrophage migration inhibitory factorHomo sapiens (human)
phenylpyruvate tautomerase activityMacrophage migration inhibitory factorHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular regionMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
nucleoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytoplasmMacrophage migration inhibitory factorHomo sapiens (human)
cytosolMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneMacrophage migration inhibitory factorHomo sapiens (human)
cell surfaceMacrophage migration inhibitory factorHomo sapiens (human)
vesicleMacrophage migration inhibitory factorHomo sapiens (human)
secretory granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular exosomeMacrophage migration inhibitory factorHomo sapiens (human)
ficolin-1-rich granule lumenMacrophage migration inhibitory factorHomo sapiens (human)
extracellular spaceMacrophage migration inhibitory factorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID598324Cytotoxicity against mouse RAW264.7 cells assessed as cell survival rate at 10 uM by MTT assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Discovery of indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL).
AID1877333Inhibition of inhibition of MIF tautomerase (unknown origin) in MIF-induced mouse RAW264.7 cells assessed as reduction in cell migration relative to control2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1877332Potency index ratio of ISO-1 IC50 to test compound IC50 for inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1761175Giardicidal activity against Giardia intestinalis WB ATCC 30957 incubated for 48 hrs by hemocytometric counting method2021European journal of medicinal chemistry, Feb-05, Volume: 211The giardicidal activity of lobendazole, fabomotizole, tenatoprazole and ipriflavone: A ligand-based virtual screening and in vitro study.
AID471225Osteogenic effect on human MADS cells assessed as extracellular matrix calcification at 10 uM after 13 days by using alizarin red S dye2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.
AID1761178Giardicidal activity against albendazole-resistant Giardia intestinalis incubated for 48 hrs by hemocytometric counting method2021European journal of medicinal chemistry, Feb-05, Volume: 211The giardicidal activity of lobendazole, fabomotizole, tenatoprazole and ipriflavone: A ligand-based virtual screening and in vitro study.
AID1290670Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay2016Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7
Cyclolinopeptides, cyclic peptides from flaxseed with osteoclast differentiation inhibitory activity.
AID1761176Giardicidal activity against metronidazole-resistant Giardia intestinalis incubated for 48 hrs by hemocytometric counting method2021European journal of medicinal chemistry, Feb-05, Volume: 211The giardicidal activity of lobendazole, fabomotizole, tenatoprazole and ipriflavone: A ligand-based virtual screening and in vitro study.
AID1877336Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability up to 100 uM by CCK8 assay2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID471227Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-stimulated osteoclastogenesis at 10 uM by TRAP assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.
AID32848Effect on alkaline phosphatase activity compared to control in culture of rat bone marrow stromal cells, 10E-5 M concentration1999Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4
Synthesis of novel 2-benzothiopyran and 3-benzothiepin derivatives and their stimulatory effect on bone formation.
AID1450306Inhibition of RANKL-stimulated osteoclastogenesis in mouse RAW264 cells assessed as reduction in TRAP activity at 20 uM measured after 72 hrs by microscopic analysis2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Synthesis of novel 5,6-dehydrokawain analogs as osteogenic inducers and their action mechanisms.
AID1761179Giardicidal activity against nitazoxanide-resistant Giardia intestinalis incubated for 48 hrs by hemocytometric counting method2021European journal of medicinal chemistry, Feb-05, Volume: 211The giardicidal activity of lobendazole, fabomotizole, tenatoprazole and ipriflavone: A ligand-based virtual screening and in vitro study.
AID1877334Inhibition of MIF tautomerase (unknown origin) using 4-HPP as substrate preincubated for 1 hr followed by substrate addition2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID471222Cytotoxicity against human ADSC at 10 uM after 3 days by MTT assay2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.
AID1364811Anti-osteoporotic activity in bovine bone assessed as bone resorption of osteoclast at 1 x 10'-8 mol/L after 8 days by toluidine blue staining-based method2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Rapid, microwave-accelerated synthesis and anti-osteoporosis activities evaluation of Morusin scaffolds and Morusignin L scaffolds.
AID1877335Reversal inhibition of MIF tautomerase (unknown origin) at 0.5 mM using 4-HPP as substrate preincubated for 30 min followed by 100 fold dilution by dilution assay2022Bioorganic & medicinal chemistry letters, 01-01, Volume: 55Repurposing old drugs as novel inhibitors of human MIF from structural and functional analysis.
AID1364805Induction of osteoblast proliferation in mouse MC3T3-E1 cells assessed a growth rate relative to untreated control at 10'-8 mol/L after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Rapid, microwave-accelerated synthesis and anti-osteoporosis activities evaluation of Morusin scaffolds and Morusignin L scaffolds.
AID1761177Giardicidal activity against Giardia intestinalis IMSS isolate incubated for 48 hrs by hemocytometric counting method2021European journal of medicinal chemistry, Feb-05, Volume: 211The giardicidal activity of lobendazole, fabomotizole, tenatoprazole and ipriflavone: A ligand-based virtual screening and in vitro study.
AID598325Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive multi-nucleated cells at 10 uM after 5 days2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Discovery of indeno[1,2-c]quinoline derivatives as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand (RANKL).
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (244)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (7.38)18.7374
1990's119 (48.77)18.2507
2000's48 (19.67)29.6817
2010's40 (16.39)24.3611
2020's19 (7.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.99 (24.57)
Research Supply Index5.72 (2.92)
Research Growth Index5.17 (4.65)
Search Engine Demand Index72.05 (26.88)
Search Engine Supply Index3.83 (0.95)

This Compound (28.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials47 (18.22%)5.53%
Reviews29 (11.24%)6.00%
Case Studies4 (1.55%)4.05%
Observational0 (0.00%)0.25%
Other178 (68.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]